1 Study Matches
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients with Multiple System Atrophy (MSA)
18331A (AMULET - Delay Multiple System Atrophy) is a Phase 2, placebo-controlled trial designed to assess the efficacy, safety and tolerability of Lu AF82422 in subjects with MSA MSA-C or MSA-P). The study is planned to consist of a screening period of 4 weeks, a randomization period of 2 weeks and a double-blind treatment period of 48 to 72 weeks . Approximately 60 subjects are planned to be randomized in a 2:1 ratio to receive either Drug A, or placebo.
18 year(s) or older
Inclusion Criteria:Multiple System Atrophy
Age >=40 and <=75 at screening
Exclusion Criteria:Pregnant or breastfeeding
Unable to have MRI